1. Home
  2. SLP vs DCTH Comparison

SLP vs DCTH Comparison

Compare SLP & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Simulations Plus Inc.

SLP

Simulations Plus Inc.

HOLD

Current Price

$16.57

Market Cap

320.9M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$11.35

Market Cap

363.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLP
DCTH
Founded
1996
1988
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.9M
363.5M
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
SLP
DCTH
Price
$16.57
$11.35
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$24.00
$22.00
AVG Volume (30 Days)
385.1K
306.5K
Earning Date
04-09-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.53
EPS
0.26
N/A
Revenue
$59,577,000.00
N/A
Revenue This Year
$3.80
$24.54
Revenue Next Year
$5.90
$33.15
P/E Ratio
$61.60
$161.57
Revenue Growth
10.52
N/A
52 Week Low
$11.09
$8.12
52 Week High
$34.01
$18.23

Technical Indicators

Market Signals
Indicator
SLP
DCTH
Relative Strength Index (RSI) 72.88 61.37
Support Level $16.26 $10.17
Resistance Level $19.29 $11.99
Average True Range (ATR) 0.86 0.52
MACD 0.15 0.04
Stochastic Oscillator 79.56 63.06

Price Performance

Historical Comparison
SLP
DCTH

About SLP Simulations Plus Inc.

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: